Back

Association of peri-procedural intravenous morphine use on clinical outcomes in ST-elevation myocardial infarction treated by percutaneous coronary intervention: systematic review and meta-analysis

31 August 2019 (11:00 - 16:00)
Organised by:
Congress Presentation Part of: Poster Session 1 - High risk percutaneous coronary intervention: STEMI, CTO, atherectomy bifurcations shock Primary Percutaneous Coronary Intervention (PCI) ESC Premium Access ESC Congress 2019

About the speaker

Photo
Doctor Riley Batchelor

The Alfred Hospital, Melbourne (Australia)

26 More presentations in this session

Presentation thumbnail
Doctor D. Topal (Copenhagen, DK)
Abstract Slides
Presentation thumbnail
Doctor A. Pavlovic (Belgrade, RS)
Abstract Slides
Presentation thumbnail
Doctor C. O'connor (Limerick, IE)
Abstract Slides
Presentation thumbnail
Associate Professor D. Maximkin (Moscow, RU)
Abstract
Presentation thumbnail
Doctor D. Milasinovic (Belgrade, RS)
Abstract

Access the full session

Session thumbnail
Poster Session 1 - High risk percutaneous coronary intervention: STEMI, CTO, atherectomy bifurcations shock

The Event

Event poster

ESC Congress 2019

31 August 2019 11:00 CET
You may be interested in
thumbnail
Congress Presentation
Impact of morphine use on mortality in STEMI patients treated with primary PCI - preliminary data from a new registry
15 April 2021
thumbnail
Congress Presentation
Colchicine in patients with acute myocardial infarction: an updated meta-analysis of randomized controlled trials
27 August 2021
thumbnail
Congress Presentation
Effects of intravenous lysine acetylsalicylate versus oral aspirin on platelet responsiveness in patients with ST-segment elevation myocardial infarction
27 August 2022
thumbnail
Congress Presentation
The impact of chronic total occlusions in patient outcomes after transcatheter aortic valve implantation: a systematic review and meta-analysis
1 September 2025

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources